This is a single-arm, open-label, multi-center Phase 2 study in subjects with histologically documented CLL/SLL who have relapsed after ≥ 1 prior treatment regimen(s). The study is composed of an initial screening phase, a single-arm treatment phase, and a follow-up phase.